A practical reference on GHS-R1a: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-13 and is reviewed periodically as new material appears.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.
After he teaches them to bark on all fours to fend off cats, the family holds a memorial service for the brother. Christina again barters for oral sex from the elder daughter. The daughter rejects her offer of hair gel and demands the Hollywood VHS tapes in her bag. She watches the films (Rocky IV and Jaws) in secret and afterwards recreates scenes and quotes their dialogue. When the father discovers the tapes, he beats her with one of them, then goes to Christina's flat and hits her with her VCR, cursing her future children to be corrupted by "bad influences". The parents decide that, with Christina no longer available, they will have the son choose one of his sisters as a new sexual partner. After fondling both sisters with his eyes closed, he chooses the elder. She is uncomfortable during their sex and afterwards threatens her brother in the style of Hollywood film dialogues. During a performance for the parents' wedding anniversary, the younger daughter stops to rest, but the elder continues and dances the choreography from Flashdance, disturbing her parents. That night, she knocks out one of her dogteeth with a dumbbell and hides in the boot of her father's car. The father discovers her tooth fragments and searches for her fruitlessly. He drives to work the next day; the car sits outside the factory, unattended.
== Awards and honors == Tanzi has received numerous awards, including the two highest awards for Alzheimer's disease research: The Metlife Foundation Award for Medical Research in Alzheimer's Disease Award and The Potamkin Prize. He was included on the list of the "Harvard 100 Most Influential Alumni", and was chosen by the Geoffrey Beene Foundation as a “Rock Star of Science”. In 2015, he was named by Time to the Time 100 Most Influential People in the World list. In 2018, Tanzi was inducted into the Rhode Island Heritage Hall of Fame. He was also inducted into the Cranston Hall of Fame in 2000. Tanzi was awarded an honorary doctorate from The University of Rhode Island on May 17, 2015.
=== Innovations === The initial stages of the Industrial Revolution had much to do with larger military forces—it became easy to mass-produce weapons and thus to equip larger forces. Britain was the largest single manufacturer of armaments in this period. It supplied most of the weapons used by the coalition powers throughout the conflicts. France produced the second-largest total of armaments, equipping its own huge forces as well as those of the Confederation of the Rhine and other allies. Napoleon showed innovative tendencies in his use of mobility to offset numerical disadvantages, as demonstrated in the rout of the Austro–Russian forces in 1805 in the Battle of Austerlitz. The French Army redefined the role of artillery, forming independent, mobile units, as opposed to the previous tradition of attaching artillery pieces in support of troops. The semaphore system had allowed the French War-Minister, Carnot, to communicate with French forces on the frontiers throughout the 1790s. The French continued to use this system throughout the Napoleonic wars. Aerial surveillance was used for the first time when the French used a hot-air balloon to survey coalition positions before the Battle of Fleurus, on 26 June 1794.
=== MeSH D12.644.276 – intercellular signaling peptides and proteins === MeSH D12.644.276.100 – angiogenic proteins MeSH D12.644.276.100.100 – angiopoietins MeSH D12.644.276.100.100.100 – angiopoietin-1 MeSH D12.644.276.100.100.200 – angiopoietin-2 MeSH D12.644.276.100.450 – angiostatic proteins MeSH D12.644.276.100.450.500 – angiostatins MeSH D12.644.276.100.450.750 – endostatins MeSH D12.644.276.100.800 – vascular endothelial growth factors MeSH D12.644.276.100.800.200 – vascular endothelial growth factor a MeSH D12.644.276.100.800.300 – vascular endothelial growth factor b MeSH D12.644.276.100.800.400 – vascular endothelial growth factor c MeSH D12.644.276.100.800.500 – vascular endothelial growth factor d MeSH D12.644.276.100.800.600 – vascular endothelial growth factor, endocrine-gland-derived MeSH D12.644.276.174 – cytokines MeSH D12.644.276.174.050 – autocrine motility factor MeSH D12.644.276.174.200 – chemokines MeSH D12.644.276.174.200.070 – beta-thromboglobulin MeSH D12.644.276.174.200.100 – chemokines, c MeSH D12.644.276.174.200.110 – chemokines, cc MeSH D12.644.276.174.200.120 – chemokines, cxc MeSH D12.644.276.174.200.130 – chemokines, cx3c MeSH D12.644.276.174.200.508 – interleukin-8 MeSH D12.644.276.174.200.600 – macrophage inflammatory proteins MeSH D12.644.276.174.200.600.500 – macrophage inflammatory protein-1 MeSH D12.644.276.174.200.610 – monocyte chemoattractant proteins MeSH D12.644.276.174.200.610.600 – monocyte chemoattractant protein-1 MeSH D12.644.276.174.200.700 – platelet factor 4 MeSH D12.644.276.174.200.750 – rantes MeSH D12.644.276.174.400 – growth substances MeSH D12.644.276.174.400.442 – hematopoietic cell growth factors MeSH D12.644.276.174.400.442.240 – colony-stimulating factors MeSH D12.644.276.174.400.442.240.075 – colony-stimulating factors, recombinant MeSH D12.644.276.174.400.442.240.075.350 – granulocyte colony stimulating factor, recombinant MeSH D12.644.276.174.400.442.240.075.350.275 – filgrastim MeSH D12.644.276.174.400.442.240.075.375 – granulocyte macrophage colony-stimulating factors, recombinant MeSH D12.644.276.174.400.442.240.150 – erythropoietin MeSH D12.644.276.174.400.442.240.150.250 – erythropoietin, recombinant MeSH D12.644.276.174.400.442.240.150.250.250 – epoetin alfa MeSH D12.644.276.174.400.442.240.350 – granulocyte colony-stimulating factor MeSH D12.644.276.174.400.442.240.350.375 – granulocyte colony stimulating factor, recombinant MeSH D12.644.276.174.400.442.240.350.375.275 – filgrastim MeSH D12.644.276.174.400.442.240.375 – granulocyte-macrophage colony-stimulating factor MeSH D12.644.276.174.400.442.240.375.275 – granulocyte macrophage colony-stimulating factors, recombinant MeSH D12.644.276.174.400.442.240.400 – interleukin-3 MeSH D12.644.276.174.400.442.240.500 – macrophage colony-stimulating factor MeSH D12.644.276.174.400.442.240.750 – thrombopoietin MeSH D12.644.276.174.400.442.800 – stem cell factor MeSH D12.644.276.174.400.505 – interleukins MeSH D12.644.276.174.400.505.501 – interleukin-1 MeSH D12.644.276.174.400.505.502 – interleukin-2 MeSH D12.644.276.174.400.505.503 – interleukin-3 MeSH D12.644.276.174.400.505.504 – interleukin-4 MeSH D12.644.276.174.400.505.505 – interleukin-5 MeSH D12.644.276.174.400.505.506 – interleukin-6 MeSH D12.644.276.174.400.505.507 – interleukin-7 MeSH D12.644.276.174.400.505.508 – interleukin-8 MeSH D12.644.276.174.400.505.509 – interleukin-9 MeSH D12.644.276.174.400.505.510 – interleukin-10 MeSH D12.644.276.174.400.505.511 – interleukin-11 MeSH D12.644.276.174.400.505.512 – interleukin-12 MeSH D12.644.276.174.400.505.513 – interleukin-13 MeSH D12.644.276.174.400.505.514 – interleukin-14 MeSH D12.644.276.174.400.505.515 – interleukin-15 MeSH D12.644.276.174.400.505.516 – interleukin-16 MeSH D12.644.276.174.400.505.517 – interleukin-17 MeSH D12.644.276.174.400.505.518 – interleukin-18 MeSH D12.644.276.174.400.800 – transforming growth factor beta MeSH D12.644.276.174.420 – hepatocyte growth factor MeSH D12.644.276.174.440 – interferons MeSH D12.644.276.174.440.890 – interferon type i MeSH D12.644.276.174.440.890.125 – interferon type i, recombinant MeSH D12.644.276.174.440.890.125.100 – interferon alfa-2a MeSH D12.644.276.174.440.890.125.150 – interferon alfa-2b MeSH D12.644.276.174.440.890.125.200 – interferon alfa-2c MeSH D12.644.276.174.440.890.250 – interferon-alpha MeSH D12.644.276.174.440.890.250.100 – interferon alfa-2a MeSH D12.644.276.174.440.890.250.150 – interferon alfa-2b MeSH D12.644.276.174.440.890.250.200 – interferon alfa-2c MeSH D12.644.276.174.440.890.275 – interferon-beta MeSH D12.644.276.174.440.893 – interferon type ii MeSH D12.644.276.174.440.893.510 – interferon-gamma, recombinant MeSH D12.644.276.174.480 – lymphokines MeSH D12.644.276.174.480.350 – interferon type ii MeSH D12.644.276.174.480.372 – interleukin-2 MeSH D12.644.276.174.480.428 – leukocyte migration-inhibitory factors MeSH D12.644.276.174.480.438 – lymphotoxin MeSH D12.644.276.174.480.615 – macrophage-activating factors MeSH D12.644.276.174.480.615.350 – interferon type ii MeSH D12.644.276.174.480.625 – macrophage migration-inhibitory factors MeSH D12.644.276.174.480.640 – neuroleukin MeSH D12.644.276.174.480.700 – suppressor factors, immunologic MeSH D12.644.276.174.480.750 – transfer factor MeSH D12.644.276.174.500 – monokines MeSH D12.644.276.174.500.400 – interleukin-1 MeSH D12.644.276.174.500.800 – tumor necrosis factor-alpha MeSH D12.644.276.174.750 – tumor necrosis factors MeSH D12.644.276.174.750.500 – lymphotoxin MeSH D12.644.276.174.750.750 – tumor necrosis factor-alpha MeSH D12.644.276.211 – endothelial growth factors MeSH D12.644.276.249 – endothelins MeSH D12.644.276.249.225 – endothelin-1 MeSH D12.644.276.249.235 – endothelin-2 MeSH D12.644.276.249.245 – endothelin-3 MeSH D12.644.276.500 – ephrins MeSH D12.644.276.500.100 – ephrin-A1 MeSH D12.644.276.500.200 – ephrin-A2 MeSH D12.644.276.500.300 – ephrin-A3 MeSH D12.644.276.500.400 – ephrin-A4 MeSH D12.644.276.500.500 – ephrin-A5 MeSH D12.644.276.500.600 – ephrin-b1 MeSH D12.644.276.500.700 – ephrin-b2 MeSH D12.644.276.500.800 – ephrin-b3 MeSH D12.644.276.625 – epidermal growth factor MeSH D12.644.276.750 – fibroblast growth factors MeSH D12.644.276.750.110 – fibroblast growth factor 1 MeSH D12.644.276.750.120 – fibroblast growth factor 2 MeSH D12.644.276.750.130 – fibroblast growth factor 3 MeSH D12.644.276.750.140 – fibroblast growth factor 4 MeSH D12.644.276.750.150 – fibroblast growth factor 5 MeSH D12.644.276.750.160 – fibroblast growth factor 6 MeSH D12.644.276.750.170 – fibroblast growth factor 7 MeSH D12.644.276.750.180 – fibroblast growth factor 8 MeSH D12.644.276.750.190 – fibroblast growth factor 9 MeSH D12.644.276.750.200 – fibroblast growth factor 10 MeSH D12.644.276.812 – i-kappa b kinase MeSH D12.644.276.875 – kinins MeSH D12.644.276.875.169 – bradykinin MeSH D12.644.276.875.169.400 – kallidin MeSH D12.644.276.875.654 – kininogens MeSH D12.644.276.875.654.350 – kininogen, high-molecular-weight MeSH D12.644.276.875.654.400 – kininogen, low-molecular-weight MeSH D12.644.276.875.900 – tachykinins MeSH D12.644.276.875.900.354 – eledoisin MeSH D12.644.276.875.900.475 – kassinin MeSH D12.644.276.875.900.500 – neurokinin a MeSH D12.644.276.875.900.550 – neurokinin b MeSH D12.644.276.875.900.800 – physalaemin MeSH D12.644.276.875.900.866 – substance p MeSH D12.644.276.937 – neuregulins MeSH D12.644.276.937.750 – neuregulin-1 MeSH D12.644.276.952 – parathyroid hormone-related protein MeSH D12.644.276.968 – platelet-derived growth factor MeSH D12.644.276.968.650 – proto-oncogene proteins c-sis MeSH D12.644.276.976 – somatomedins MeSH D12.644.276.976.400 – insulin-like growth factor i MeSH D12.644.276.976.420 – insulin-like growth factor ii MeSH D12.644.276.984 – transforming growth factors MeSH D12.644.276.984.700 – transforming growth factor alpha MeSH D12.644.276.984.720 – transforming growth factor beta MeSH D12.644.276.992 – tumor necrosis factors MeSH D12.644.276.992.500 – lymphotoxin MeSH D12.644.276.992.750 – tumor necrosis factor-alpha MeSH D12.644.276.996 – wnt proteins MeSH D12.644.276.996.500 – wnt1 protein MeSH D12.644.276.996.750 – wnt2 protein
=== Economics === The initial price proposed by Merck in 1987 was US$6 per treatment, which was unaffordable for patients who most needed ivermectin. The company donated hundreds of millions of courses of treatments since 1988 in more than 30 countries. Between 1995 and 2010, using donated ivermectin to prevent river blindness, the program is estimated to have prevented seven million years of disability at a cost of US$257 million. Ivermectin is considered an inexpensive drug. As of 2019, ivermectin tablets (Stromectol) in the United States are the least expensive treatment option for lice in children at approximately US$9.30, while Sklice, an ivermectin lotion, cost around US$300 for 120 mL (4 US fl oz). As of 2019, the cost effectiveness of treating scabies and lice with ivermectin has not been studied.
Sources: en.wikipedia.org
Some hematomas are visible under the surface of the skin (commonly called bruises) or possibly felt as masses or lumps. Lumps may be caused by the limitation of the blood to a sac, subcutaneous or intramuscular tissue space isolated by fascial planes. This is an anatomical feature that helps prevent injuries from causing massive blood loss. In most cases a hematoma as a sac of blood eventually dissolves; however, in some cases it may continue to grow due to blood seepage or show no change. If the sac of blood does not disappear, then it may need to be surgically cleaned out or repaired. The slow process of reabsorption of hematomas can allow the broken down blood cells and hemoglobin pigment to move in the connective tissue. For example, an injury to the base of the thumb might cause a hematoma that moves slowly throughout the finger over the course of a week. Gravity is the main determinant of this process. Hematomas on articulations can reduce mobility of a member and present roughly the same symptoms as a fracture. In most cases, movement and exercise of the affected muscle is the best way to introduce the collection back into the bloodstream.
Pending the resolution of litigation, the Cherokee Freedman had all rights as full Cherokee Nation citizens, including voting rights and access to tribal services. In early 2011, the tribal district court ruled that the special election in 2007 on the constitutional amendment was unconstitutional, as it excluded Freedmen from voting. The Nation appealed. On August 22, 2011, the Cherokee Supreme Court upheld the results of the 2007 special election. Chuck Trimble, a former executive director of the National Congress of American Indians, characterized the decision as the "Cherokee Dred Scott Decision", for depriving a group of citizenship. At the same time, the Cherokee Supreme Court ordered a special run-off election to be held September 24, 2011 to settle the office of Principal Chief. Earlier voting in this year's election had been so close that the incumbent Chad Smith and challenger Bill John Baker, longtime Cherokee National Council member, had each twice been declared the winner. On September 11, the nation sent letters to Freedmen, notifying them of their loss of citizenship and voting rights. The US Department of Housing and Urban Development froze $33 million in funds to the Cherokee Nation while studying the case, pursuant to a stipulation in the 2008 congressional renewal of Self-Determination Act.
Menu items offered at Boston Market included various meats and sides, such as rotisserie chicken (whole, half, or quarter), apple pie, carved chicken sandwich, chicken salad sandwich, chicken noodle soup, chicken pot pie, cilantro lime rice, creamed spinach, Cobb salad, cornbread, garlic dill potatoes, mashed potatoes (with gravy), meatloaf and meatloaf sandwich, desserts (salted caramel lava cake, chocolate cake, or chocolate chip cookies), prime rib, ribs (beef, with sauce), steamed vegetables (e.g., broccoli), sweet potato casserole, and turkey (roasted). Many of the chicken items included rotisserie chicken, and the rotisserie oven was also used to cook other meats. Boston Market offered rotisserie nuggets for a time. Boston Market also had seasonal holiday menu and catering food packages, such as for Thanksgiving dinner (a traditional U.S. holiday meal), which included items such as a whole rotisserie turkey, mashed potatoes, gravy, vegetable stuffing, spinach-artichoke dip, cranberry walnut relish, dinner rolls, and pumpkin and apple pies. The Boston Market supermarket brand is produced by Bellisio Foods. As of 2024, it continues to produce items such as chicken pot pie bites, mashed potatoes, and chicken fajita rice bowls.
== Research and development == Generate's research is centered on leveraging machine learning to program proteins for specific functions. Its platform is trained on extensive datasets comprising 160,000 protein structures and 190 million genetic sequences. This system identifies patterns linking protein sequence, structure, and function, which are then used to design new therapeutic proteins. The company's technology includes two core components: de novo protein generation, which allows for the creation of proteins without relying on existing biological templates, and an optimization suite to refine these proteins for therapeutic use. This approach addresses challenges like affinity, immunogenicity, and manufacturability. Generate has applied its platform across various modalities, including antibodies, peptides, enzymes, and antibody-drug conjugates (ADCs). Notable research outputs include antibodies targeting SARS-CoV-2 and preclinical assets in oncology, developed in collaboration with institutions like MD Anderson Cancer Center. To support its experimental work, Generate has invested in advanced facilities, such as a cryogenic electron microscopy (cryoEM) laboratory in Andover, Massachusetts. This lab enables the collection of high-resolution protein interaction data to further train its computational models. Generate's pipeline includes clinical and preclinical candidates addressing conditions like severe asthma and non-small cell lung cancer.
== Blood doping == Blood doping is the injection of red blood cells, related blood products that contain red blood cells, or artificial oxygen containers. This is done by extracting and storing one's own blood prior to an athletic competition, well in advance of the competition so that the body can replenish its natural levels of red blood cells, and subsequently injecting the stored blood immediately before competition. The resulting unnatural level of red blood cells improves oxygen transport and athletic endurance; thus, it is prohibited in most events. It is often used in extreme sports like cycling, snowboarding, and skiing where endurance is highly valued. The most famous example of this type of doping is Lance Armstrong's performance in the Tour de France.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
Dry powder is typically kept frozen, desiccated, and protected from light. Avoiding moisture exposure and large temperature swings helps slow degradation. Storage recommendations vary by supplier and should be followed for the specific material.